A Phase 3 interventional study of HX575, solution for injection (s.c.) and ERYPO®, Janssen-Cilag, solution for injection (s.c.) in Anemia, sponsored by Sandoz. Completed at 19 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-05.
Sponsored by Sandoz (formerly part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies testing Epoetin Alfa in Anemia — 2 open to participants now, 3 under way, 2 of them phase 3. Epoetin Alfa · Anemia.
Among the 126 studies testing Epoetin Alfa in Anemia, this one is the 44th largest by enrollment of the 112 interventional ones that give a count, is one of 14 that started in 2004, is one of 45 in phase 3, and was the 102nd registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →2 of the 126 studies testing Epoetin Alfa in Anemia are open now, in 1 country. Recruiting first, the newest first:
Services Hospital, Lahore · Sites in Pakistan
Ages 18–65
Geoff Block
Ages 18+
By country, each count listing its studies:
Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 45 · Phase 3 46 · Phase 4 20
First in 1988; this study’s year is marked. 14 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 114 is close to the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 71 across the 112 interventional studies. Of the 114 that completed or were terminated, 23 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
95 of 126 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sandoz, one of the names counted as Novartis. Under that name alone:
Sandoz is the lead sponsor of 139 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
19 studies in Anemia by Novartis: 1 open now, 2 under way, 2 of them phase 3. Of 16 finished, 11 (69%) have results posted.
Among the 19 studies in Anemia by Novartis, this one is the 8th largest by enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2004, is one of 12 in phase 3, and was the 7th registered.
Novartis’s Anemia studies by the year they started, since 2004.
2 of the studies testing Epoetin Alfa in Anemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07565701Phase 3Geoff BlockSafety and Efficacy of a Phased Transition From Epogen to Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Subjects Receiving In-Center Hemodialysis | 2027-04 |
| NCT07755683Services Hospital, LahoreEffect of Daprodustat and Epoetin Alpha on Anemia in Patients Not Undergoing Dialysis | 2027-02-28 |
Add all 2 to your calendar (.ics) → With an account.
Among the 126 studies testing Epoetin Alfa in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 19 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, multicenter clinical phase III study involving about 105 cancer patients aged >18 years who are receiving palliative chemotherapy and who are suffering from chemotherapy associated anemia. A standard treatment group (ERYPO®) will be included to provide a reference reflecting current standard medical practice.
Eligible patients were randomized to one of two different treatment groups (EPO HEXAL or ERYPO) in a 2:1 ratio. Patients received double-blind treatment for a period of 12 weeks. Following randomization the patients were treated subcutaneously with a dose of 150 IU/kg body weight of study drug three times per week. Dose adjustments to 300 IU/kg body weight three times per week were to be done if hemoglobin (Hb) increased \<1.0 g/dL or the reticulocyte count increased \<40,000 /μl after 4 weeks or if Hb increased \<2.0 g/dL after 8 weeks of treatment. The primary endpoint was the Hb response in the EPO HEXAL group during weeks 5-12 of the study defined as absolute increase in Hb value of 2.0 g/dL from the mean value of the screening/baseline period in the absence of red blood cell transfusion during the preceding 4 weeks. For that purpose, Hb levels were measured at the weekly study visits by a central laboratory. Further parameters of treatment efficacy, safety and tolerability were recorded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HX575 (erythropoietin alfa of the Sponsor Hexal AG). Eligible patients to be randomized in ratio 2:1 and to be subcutaneously treated (solution for injection (s.c.)) for 12 weeks with HX575 in pre-filled syringes. The maximum weekly dose of HX575 was 300 IU/kg body weight to maintain hemoglobin levels in the therapeutic range. Application of the drug required at least once per week and allowed maximum three times per week.
Drug: HX575, solution for injection (s.c.)
ERYPO® Janssen-Cilag, Germany. Eligible patients were treated subcutaneously (solution for injection (s.c.)) with ERYPO® (Janssen-Cilag, Germany) in pre-filled syringes for 12 weeks.The maximum weekly dose of HX575 was 300 IU/kg body weight to maintain hemoglobin levels in the therapeutic range. Application of the drug required at least once per week and allowed maximum three times per week.
Drug: ERYPO®, Janssen-Cilag, solution for injection (s.c.)
1000, 2000, 4000, 8000 and 10.000 IU of rh erythropoiethin
Also known as: Binocrit, Erythropoeitin alfa Hexal, Abseamed
1000, 2000, 4000, 8000 and 10.000 IU of epoetin alfa
Also known as: Eprex
Efficacy of HX575 in the Treatment of Chemotherapy Associated Anemia
Proportion of patients with a change in hemoglobin levels more than 2 g/dL under treatment with HX575, estimated between weeks 5-12.
Time frame: 5-12 weeks
23 cancer centers, in Germany and Romania .
| Milestone | HX575 Epoetin Alfa Hexal AG | ERYPO® Janssen-Cilag |
|---|---|---|
| Started | 74 | 40 |
| Completed | 41 | 17 |
| Not completed | 33 | 23 |
| Withdrew: Withdrawal by subject | 6 | 8 |
| Withdrew: Lack of efficacy | 3 | 1 |
| Withdrew: Clinical deterioration | 1 | 0 |
| Withdrew: Adverse event | 9 | 7 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Death | 10 | 5 |
| Withdrew: Progression of disease | 1 | 0 |
Proportion of patients with a change in hemoglobin levels more than 2 g/dL under treatment with HX575, estimated between weeks 5-12.
| Participants | HX575 Epoetin Alfa Hexal AG | ERYPO® Janssen-Cilag |
|---|---|---|
| Efficacy of HX575 in the Treatment of Chemotherapy Associated Anemia | 37 | 15 |
Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HX575 Epoetin Alfa Hexal AG | 18/74 (24.3%) | 34/74 (45.9%) | 62/74 (83.8%) |
| ERYPO® Janssen-Cilag | 12/40 (30%) | 18/40 (45%) | 30/40 (75%) |
| Event | HX575 Epoetin Alfa Hexal AG | ERYPO® Janssen-Cilag |
|---|---|---|
| Neoplasms malignant site unspecified NECNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 6/74 | 6/40 |
| Renal failure and impairmentRenal and urinary disorders | 2/74 | 5/40 |
| Asthenic conditionsGeneral disorders | 4/74 | 0/40 |
| Metastases to specified sitesNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/74 | 2/40 |
| Peritoneal and retroperitoneal disordersGastrointestinal disorders | 1/74 | 2/40 |
| Febrile disordersGeneral disorders | 0/74 | 2/40 |
| Urinary abnormalitiesRenal and urinary disorders | 1/74 | 2/40 |
| Renal obstructive disordersRenal and urinary disorders | 0/74 | 2/40 |
| Ventricular arrhythmias and cardiac arrestCardiac disorders | 2/74 | 2/40 |
| Ischaemic coronary artery disordersCardiac disorders | 0/74 | 2/40 |
| Event | HX575 Epoetin Alfa Hexal AG | ERYPO® Janssen-Cilag |
|---|---|---|
| NauseaGastrointestinal disorders | 17/74 | 14/40 |
| VomitingGastrointestinal disorders | 13/74 | 9/40 |
| AstheniaGeneral disorders | 15/74 | 6/40 |
| AnorexiaMetabolism and nutrition disorders | 12/74 | 7/40 |
| ConstipationGastrointestinal disorders | 9/74 | 6/40 |
| FatigueGeneral disorders | 5/74 | 6/40 |
| Abdominal painGastrointestinal disorders | 9/74 | 5/40 |
| PyrexiaGeneral disorders | 9/74 | 4/40 |
| DiarrhoeaGastrointestinal disorders | 4/74 | 4/40 |
| Oedema peripheralGeneral disorders | 5/74 | 4/40 |
50 patients found to have a major protocol violation , excluded from the ITT population only (31 and 19 in EPO HEXAL and ERYPO groups), none from the Safety Analysis population. Major deviations: early patient withdrawal (consent or due to AE), and lack of endpoint value in observation period (no Hemoglobin value over weeks 5 to 12)
| Age, Customized(Participants) | HX575 Epoetin Alfa Hexal AG | ERYPO® Janssen-Cilag | Total |
|---|---|---|---|
| 18-39 years | 3 | 3 | 6 |
| 40-64 years | 43 | 18 | 61 |
| ≥65 years | 28 | 19 | 47 |
| Sex: Female, Male(Participants) | HX575 Epoetin Alfa Hexal AG | ERYPO® Janssen-Cilag | Total |
|---|---|---|---|
| Female | 41 | 17 | 58 |
| Male | 33 | 23 | 56 |
| Region of Enrollment(Participants) | HX575 Epoetin Alfa Hexal AG | ERYPO® Janssen-Cilag | Total |
|---|---|---|---|
| Romania | 36 | 18 | 54 |
| Germany | 38 | 22 | 60 |
| most frequent site of primary malignancy(Participants) | HX575 Epoetin Alfa Hexal AG | ERYPO® Janssen-Cilag | Total |
|---|---|---|---|
| ovary | 17 | 7 | 24 |
| lung | 13 | 6 | 19 |
| pancreas | 5 | 4 | 9 |
| stomach | 4 | 4 | 8 |
| breast | 8 | 3 | 11 |
| other | 27 | 16 | 43 |
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Nov 2004, a primary completion of Jul 2005 and a completion of Dec 2005. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2017, 12 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epoetin Alfa